| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | ACTU | Common Stock | 125K | Aug 14, 2024 | Direct |
This Form 3 is being filed by Bios 2024 Co-Invest, LP to reflect their admission as members into the "group" (for Section 13 and Section 16 purposes) previously composed of Bios Fund I, LP, Bios Fund I QP, LP, Bios Fund II, LP, Bios Fund II QP, LP, Bios Fund II NT, LP, Bios Fund III, LP, Bios Fund III QP, LP, Bios Fund III NT, LP, BP Directors, LP, Bios Actuate Co-Invest I, LP, Bios Actuate Co-Invest II, LP, Bios Acuate Co-Invest III, LP, Bios Clinical Opportunity Fund, LP, Bios Equity Partners III, LP, Bios Equity Partners II, LP, Bios Equity Partners, LP, Bios Equity COF, LP, Bios Capital Management, LP, Cavu Management, LP, Bios Advisors GP, LLC, Cavu Advisors, LLC, Aaron G.L. Fletcher and Leslie W. Kreis. The reporting person may be deemed to be a "director by deputization" as the result of Aaron G.L. Fletcher's position as a director of the issuer. Exhibit 24 - Power of Attorney